Bavarian Nordic is a fully integrated biotechnology company focused on the development, manufacturing and commercialization of cancer immunotherapies and vaccines for infectious diseases.
Our pipeline has multiple clinical stage development programs, including three Phase 3 programs.
Bavarian Nordic is committed to providing our shareholders and the media with reliable and transparent information about our business, development programs and results in an open and timely manner
Bavarian Nordic offers a challenging international working environment in which job satisfaction and personal growth have a high priority.
Strong pipeline progress in 2016 - Financial targets met - Pivotal events expected in 2017
We are pioneering the next generation of cancer immunotherapies and vaccines for infectious diseases
Leveraging our unique and versatile discovery platform, our scientists are focused on bringing new and safer vaccines to the market
MVA-BN® is the platform for IMVANEX®, an approved vaccine in Europe, and the poxvirus platform has been studied extensively for cancer treatment
We have built a revenue-generating biotech company with a late stage pipeline in blockbuster markets, strong IP, and manufacturing expertise